Surgical Science Sweden (OM:SUS) Stock Rich Margins Meet A Durability Question

Surgical Science Sweden heads into this earnings reaction with a strong recent share run, up about 62% over the past month, yet still trading around SEK49.3. The stock carries a premium P/E of 27x on trailing earnings, while the latest discounted cash flow estimate sits far higher than the current price. Q2 results land in the middle of that debate. Revenue reached about SEK254.5m and adjusted profitability hit the company’s 15% EBIT target, powered by a rich 69% gross margin and strong license income. The market now has to judge whether those margins are sustainable.

Love the rich 69% gross margin at Surgical Science Sweden but concerned about how durable that earnings quality is at a 27x P/E? Consider list of solid balance sheet and fundamentals stocks (434 results), which highlights companies that pair healthier balance sheets with strong cash generation.

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs Q2 2025: SEK 254.5m vs SEK 209.2m (up about 21.7%)
• Net Income, Q2 2026 vs Q2 2025: SEK 20.85m vs a loss of SEK 20.08m (returned to profit)
• Basic EPS, Q2 2026 vs Q2 2025: SEK 0.41 vs a loss of SEK 0.39 (returned to positive EPS)
• Gross Margin, Q2 2026: 69%, and the company’s EBIT margin target of 15% was achieved on an adjusted basis (margin profile aligned with stated profitability goal)

Prefer clear visuals instead of another wall of earnings tables and ratios for Surgical Science Sweden? View the company’s share price performance and context in a full interactive format through the company report for Surgical Science Sweden.

Surgical Science Sweden: Bull Story Meets Hard Milestones

The bullish pitch on Surgical Science Sweden is that rising simulation adoption and OEM partnerships, especially in robotics and ultrasound, will translate into higher quality recurring revenue and better margins. Q2 provides some concrete proof points. License revenue reached SEK 85m and made up 33% of sales. Management highlighted higher than modelled attach rates on Intuitive’s dV5 systems and a full renewal record on early digital subscriptions. That supports the idea of stickier, subscription-like income rather than one off hardware deals.

At the same time, the group hit its 15% adjusted EBIT margin target for both Q2 and the first half. Gross margin reached 69%, with simulator margins improving alongside the richer license mix. Ultrasound revenue grew 34% year on year, helped by last year’s Intelligent Ultrasound acquisition, which aligns with the thesis that this segment can become a more meaningful earnings contributor over time.

Compare these rich margins and growing license mix with what the street is pricing in at SEK49.3. See the consensus price target analysis for Surgical Science Sweden to check how analyst targets line up with the current earnings story.

Surgical Science Sweden Bear Case: Volatility Not Yet Tamed

The cautious view on Surgical Science Sweden is that revenue is too concentrated and lumpy, margins fragile and partner dependence high. Q2 chips away at parts of that, but it does not fully clear the bear hurdles.

Revenue of about SEK 255m and a 15% adjusted EBIT margin show that prior integration and pricing work are feeding through. A 69% gross margin and SEK 85m of license revenue, about 33% of sales, directly challenge the idea that mix will stay structurally low quality. However, management is still flagging lumpy license and development flows, with working capital tied up in project deliveries and accrued license income. That keeps visibility limited.

On partner dependence, better than expected Intuitive attach and renewals reduce immediate downside risk, but management still treats those contracts as a key sensitivity. The cautious thesis on volatility and reliance is weakened but not broken.

After such lumpy license flows and a volatile share price over recent months, review our independent risk analysis for Surgical Science Sweden which shows 2 important warning signs to identify any deeper structural issues.

Take Control Of Your Next Move

If the mix of rich margins and lumpy license income at Surgical Science Sweden has your attention, register for free with Simply Wall St and add it to a Watchlist to keep an eye on price versus fair value and wait for a setup that fits your plan. Once you own shares, use the Portfolio Command Center to cut through noise and focus on concise updates that matter for your holdings. For longer term ideas, tap into the crowd insight inside the Community to see how other investors are thinking about similar risks and catalysts. By spotting both hidden drivers and potential red flags early, you put yourself in a better position to stay ahead of the market.

Seeking Alternatives Beyond Surgical Science Sweden?

Fresh stock ideas can move quickly once the crowd catches on. Scan these curated screens before momentum takes off and information goes stale. Consider exploring them early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com